Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer

被引：0

作者：

Kikuchi, Y., Sr. ^{[1
,2
,3
,4
,5
,6
,7
]}

Kouta, H. ^{[1
,2
,3
,4
,5
,6
,7
]}

Kikuchi, R. ^{[1
,2
,3
,4
,5
,6
,7
]}

Takano, M. ^{[1
,2
,3
,4
,5
,6
,7
]}

Kita, T. ^{[1
,2
,3
,4
,5
,6
,7
]}

Kudoh, K. ^{[1
,2
,3
,4
,5
,6
,7
]}

Aoki, D. ^{[1
,2
,3
,4
,5
,6
,7
]}

Sugiyama, T. ^{[1
,2
,3
,4
,5
,6
,7
]}

Isonishi, S. ^{[1
,2
,3
,4
,5
,6
,7
]}

机构：

[1] Ohki Mem Kikuchi Canc Clin Women, Tokorozawa, Saitama, Japan

[2] Natl Def Med Coll, Tokorozawa, Saitama 359, Japan

[3] Teikyo Univ, Sch Med, Tokyo 173, Japan

[4] Nishisaitama Cent Hosp, Tokorozawa, Saitama, Japan

[5] Keio Univ, Sch Med, Tokyo, Japan

[6] Iwate Med Univ, Morioka, Iwate 020, Japan

[7] Jikei Univ, Sch Med, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5547

引用

页数：2

共 50 条

[21] Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer.
Kikuchi, Y.
Takano, M.
Goto, T.
Kouta, H.
Kikuchi, R.
Kudoh, K.
Kita, T.
Furuya, K.
Umayahara, K.
Takizawa, K.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[22] The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer
Kita, T
Kikuchi, Y
Takano, M
Suzuki, M
Oowada, M
Konno, R
Yamamoto, K
Inoue, H
Seto, H
Yamamoto, T
Shimizu, K
GYNECOLOGIC ONCOLOGY, 2004, 92 (03) : 813 - 818
[23] Recurrent ovarian undifferentiated carcinoma resembling hepatoid morphology treated with pegylated liposomal doxorubicin and bevacizumab
Ishiguro, Tatsuya
Kashima, Kastunori
Yachida, Nozomi
Motoyama, Teiichi
Enomoto, Takayuki
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2017, 43 (05) : 957 - 961
[24] Pembrolizumab plus pegylated liposomal Doxorubicin for Patients with Ovarian Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (01) : 19 - 20
[25] Trabectedin in combination with pegylated liposomal doxorubicin for patients with ovarian cancer
Tavella, K.
Villanucci, A.
Vannini, L.
Montelatici, S.
Lavacchi, D.
Boni, L.
Tomcikova, D.
Amunni, G.
Mazzei, T.
ANNALS OF ONCOLOGY, 2016, 27
[26] Pegylated liposomal doxorubicin in ovarian cancer patients with renal compromise
Basu, C. K.
Mukhopadhyay, A.
Pandey, R.
Dey, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[27] Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients
Manso, L.
Valdiviezo, N.
Sepulveda, J.
Ciruelos, E.
Mendiola, C.
Ghanem, I.
Vega, E.
Manneh, R.
Dorta, M.
Cortes-Funes, H.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (06): : 467 - 471
[28] THE ROLE OF PEGYLATED LIPOSOMAL DOXORUBICIN AND WEEKLY PACLITAXEL WITH OR WITHOUT BEVACIZUMAB IN PROLONGING THE PLATINUM-FREE INTERVAL IN EPITHELIAL OVARIAN CANCER
El-Modir, Ahmed
Doyle, Yvonne
Fernando, Indrajit
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A317 - A317
[29] Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients
L. Manso
N. Valdiviezo
J. Sepúlveda
E. Ciruelos
C. Mendiola
I. Ghanem
E. Vega
R. Manneh
M. Dorta
H. Cortés-Funes
Clinical and Translational Oncology, 2013, 15 : 467 - 471
[30] Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-Overexpressing metastatic breast cancer
Andreopoulou, Eleni
Gaiotti, Darci
Kim, Eugene
Volm, Matthew
Oratz, Ruth
Freedberg, Robin
Downey, Andrea
Vogel, Charles L.
Chia, Stephen
Muggia, Franco
CLINICAL BREAST CANCER, 2007, 7 (09) : 690 - 696

← 1 2 3 4 5 →